Literature DB >> 18398582

Comparison of 60cobalt and 192iridium sources in high dose rate afterloading brachytherapy.

Jürgen Richter1, Kurt Baier, Michael Flentje.   

Abstract

PURPOSE: (60)Co sources with dimensions identical to those of (192)Ir have recently been made available in clinical brachytherapy. A longer half time reduces demands on logistics and quality assurance and perhaps costs.
MATERIAL AND METHODS: Comparison of the physical properties of (60)Co and (192)Ir with regard to brachytherapy.
RESULTS: Required activities for the same air kerma rate are lower by a factor of 2.8 for (60)Co. Differential absorption in tissues of different densities can be neglected. Monte Carlo calculations demonstrate that integral dose due to radial dose fall off is higher for (192)Ir in comparison to (60)Co within the first 22 cm from the source (normalization at 1 cm). At larger distances this relationship is reversed.
CONCLUSION: Clinical examples for intracavitary and interstitial applications however, show practically identical dose distributions in the treatment volume.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398582     DOI: 10.1007/s00066-008-1684-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  26 in total

1.  Comparison of Axxent-Xoft, (192)Ir and (60)Co high-dose-rate brachytherapy sources for image-guided brachytherapy treatment planning for cervical cancer.

Authors:  P N Mobit; S Packianathan; R He; C C Yang
Journal:  Br J Radiol       Date:  2015-05-21       Impact factor: 3.039

2.  Study of the dosimetric differences between (192)Ir and (60)Co sources of high dose rate brachytherapy for breast interstitial implant.

Authors:  Mourougan Sinnatamby; Vivekanandan Nagarajan; Reddy Kanipakam Sathyanarayana; Gunaseelan Karunanidhi; Vivekanandam Singhavajala
Journal:  Rep Pract Oncol Radiother       Date:  2016-05-11

3.  Assessment of dose uniformity around high dose rate 192Ir and 60Co stepping sources.

Authors:  Bagher Farhood; Mahdi Ghorbani
Journal:  Radiol Phys Technol       Date:  2017-09-18

4.  125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region.

Authors:  M-W Huang; L Zheng; S-M Liu; Y Shi; J Zhang; G-Y Yu; J-G Zhang
Journal:  Strahlenther Onkol       Date:  2013-04-28       Impact factor: 3.621

5.  Gynecological brachytherapy for postoperative endometrial cancer: dosimetric analysis (Ir-192 vs Co-60).

Authors:  V Tormo Ferrero; R Duque Ugarte; M Á Berenguer Francés; R Cardenal Maciá
Journal:  Clin Transl Oncol       Date:  2017-05-17       Impact factor: 3.405

6.  Dosimetric comparison of brachytherapy sources for high-dose-rate treatment of endometrial cancer: (192)Ir, (60)Co and an electronic brachytherapy source.

Authors:  Paul N Mobit; Alex Nguyen; Satyaseelan Packianathan; Rui He; Claus C Yang
Journal:  Br J Radiol       Date:  2016-01-08       Impact factor: 3.039

7.  Dosimetric verification of source strength for HDR afterloading units with Ir-192 and Co-60 photon sources: Comparison of three different international protocols.

Authors:  Hasin A Azhari; Frank Hensley; Wilhelm Schütte; Golam A Zakaria
Journal:  J Med Phys       Date:  2012-10

8.  Dosimetric comparison between the microSelectron HDR (192)Ir v2 source and the BEBIG (60)Co source for HDR brachytherapy using the EGSnrc Monte Carlo transport code.

Authors:  M Anwarul Islam; M M Akramuzzaman; G A Zakaria
Journal:  J Med Phys       Date:  2012-10

9.  Dosimetric characterizations of GZP6 (60)Co high dose rate brachytherapy sources: application of superimposition method.

Authors:  Mohammad Taghi Bahreyni Toossi; Mahdi Ghorbani; Ali Asghar Mowlavi; Ali Soleimani Meigooni
Journal:  Radiol Oncol       Date:  2012-01-02       Impact factor: 2.991

10.  Treatment planning study of the 3D dosimetric differences between Co-60 and Ir-192 sources in high dose rate (HDR) brachytherapy for cervix cancer.

Authors:  Antony Palmer; Orla Hayman; Sarah Muscat
Journal:  J Contemp Brachytherapy       Date:  2012-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.